Orange Sail Pharma Secures Nearly $50 Million in Pre-A Financing to Advance Multispecific Antibody and ADC Pipeline

VCBeat has learned that OrangeSail Bio (“OrangeSail” or the “Company”), a biopharmaceutical company focused on the discovery and development of multispecific antibodies and antibody-drug conjugates (ADCs), announced today the completion of its Pre-A financing round, raising nearly USD 50 million.This round of financing was led by Panacea Venture and SHC, with continued support from existing shareholder HLC, and participation from several well-known investment institutions including Everjoy Fortune, Wanwu Ventures, Delian Capital, and Legendstar Capital.

The proceeds from this financing will be used to advance OrangeSail Pharma’s innovative drug pipeline, accelerate the entry of core R&D projects into clinical development, and focus on developing differentiated innovative therapies for oncology, autoimmune diseases, and other fields.

Dr. Jing Li, Founder and CEO of OrangeSail Pharmastated, “We are deeply honored to have earned the recognition and support of both new and existing investors. Over the past three years, our team has made relentless efforts, rapidly advancing multiple projects in our pipeline and achieving significant milestones in business collaborations. These positive developments underscore the company’s strong execution capabilities, innovation capacity, and business development prowess. This financing round will accelerate the entry of several core projects into clinical trials. Through independent R&D and external partnerships, we will further advance the development of differentiated innovative therapeutic solutions, create greater commercial value, and bring innovative drugs to market as soon as possible to benefit patients worldwide. Meanwhile, we will continue to attract and cultivate top talent to sustain the company’s growth and expansion.”

James Huang, Managing Partner at Panacea Venturestated: “Ruifu Medical is dedicated to identifying and supporting innovative and transformative early-stage healthcare and life sciences companies globally. As an angel investor in OrangeSail Pharma, we have witnessed the company’s growth and achievements since its inception. Under the leadership of an exceptional management team, the company has built robust technology platforms in key areas such as target discovery, protein engineering, and antibody-drug conjugate (ADC) development, which have significantly enhanced its R&D efficiency. We firmly believe that the company will continue to advance more innovative products into clinical trials and co-develop them with partners, thereby benefiting patients worldwide.”

Guo Qiushan, Partner at SHC“SHC has been closely monitoring the R&D progress of innovative bispecific antibodies and next-generation ADC drugs, and has continuously invested in leading companies in this field. As one of the first companies to establish a presence in the multi-target, multi-epitope ADC sector, Orange Bay Pharma leverages its unique target screening and combination platform, antibody engineering platform, and conjugation technology platform to build a portfolio of differentiated and First-in-Class (FIC) pipelines, demonstrating the company’s robust R&D capabilities and global vision. We believe that the team led by Dr. Li Jing will be able to bring China’s innovative biologics to the global market, providing patients with superior treatment options.”

OrangeSail Biopharma is a leading biotechnology company specializing in the discovery and development of multispecific antibodies and antibody-drug conjugates (ADCs), equipped with a highly efficient drug discovery platform as well as exceptional capabilities in translational medicine, chemistry, manufacturing, and controls (CMC), and early-stage clinical development. Since its establishment in 2021, OrangeSail Biopharma has built an extensive R&D pipeline comprising more than ten first-in-class/best-in-class (FIC/BIC) multispecific antibody and ADC candidates, primarily focusing on oncology and autoimmune diseases. Additionally, the company has established VelaVigo Bio, Inc. in the United States to advance global clinical development and collaborations.

The company’s core R&D pipeline is expected to enter clinical development in the United States and China in 2025. OrangeSail Pharma continues to expand collaborations in clinical development, technology platforms, and investor relations to maximize drug development efficiency and investment returns.